173 related articles for article (PubMed ID: 10608023)
1. Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance.
Vaughan DE
J Thromb Thrombolysis; 1995; 2(3):187-193. PubMed ID: 10608023
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells.
van Leeuwen RT; Kol A; Andreotti F; Kluft C; Maseri A; Sperti G
Circulation; 1994 Jul; 90(1):362-8. PubMed ID: 8026020
[TBL] [Abstract][Full Text] [Related]
3. Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview.
Rouch A; Vanucci-Bacqué C; Bedos-Belval F; Baltas M
Eur J Med Chem; 2015 Mar; 92():619-36. PubMed ID: 25615797
[TBL] [Abstract][Full Text] [Related]
4. The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as PAI-1 inhibitors.
Gils A
Verh K Acad Geneeskd Belg; 2006; 68(3):179-98. PubMed ID: 16796017
[TBL] [Abstract][Full Text] [Related]
5. Functional stability of plasminogen activator inhibitor-1.
Yasar Yildiz S; Kuru P; Toksoy Oner E; Agirbasli M
ScientificWorldJournal; 2014; 2014():858293. PubMed ID: 25386620
[TBL] [Abstract][Full Text] [Related]
6. The status of plasminogen activator inhibitor-1 as a therapeutic target.
Charlton P
Expert Opin Investig Drugs; 1997 May; 6(5):539-54. PubMed ID: 15989619
[TBL] [Abstract][Full Text] [Related]
7. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?
De Taeye B; Gils A; Declerck PJ
Thromb Haemost; 2004 Nov; 92(5):898-924. PubMed ID: 15543316
[TBL] [Abstract][Full Text] [Related]
8. No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.
Petersen KR; Kjems LL; Skouby SO; Andersen LF; Jespersen J
Metabolism; 1996 Jul; 45(7):833-7. PubMed ID: 8692017
[TBL] [Abstract][Full Text] [Related]
9. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.
Gils A; Declerck PJ
Thromb Haemost; 2004 Mar; 91(3):425-37. PubMed ID: 14983217
[TBL] [Abstract][Full Text] [Related]
10. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in plasma tissue plasminogen activator, plasminogen activator inhibitor-1 and beta-thromboglobulin content in ischemic stroke.
Zhuang P; Wo D; Xu ZG; Wei W; Mao HM
J Clin Neurosci; 2015 Jul; 22(7):1123-7. PubMed ID: 26002716
[TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.
Zunker P; Schick A; Padró T; Kienast J; Phillips A; Ringelstein EB
Neurol Res; 1999 Dec; 21(8):727-32. PubMed ID: 10596380
[TBL] [Abstract][Full Text] [Related]
13. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
14. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
[TBL] [Abstract][Full Text] [Related]
15. Expression of the plasminogen activator system in the human vascular wall.
Salame MY; Samani NJ; Masood I; deBono DP
Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335
[TBL] [Abstract][Full Text] [Related]
16. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms].
Banfi C; Mussoni L; Tremoli E
Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1.
Gils A; Declerck PJ
Curr Med Chem; 2004 Sep; 11(17):2323-34. PubMed ID: 15379715
[TBL] [Abstract][Full Text] [Related]
18. The ratio of plasminogen activator inhibitor type-1 activity to the concentration of plasminogen activator inhibitor type-1 protein in diabetes: adding insult to injury.
Sobel BE; Neimane D; Mack WJ; Hodis HN; Buchanan TA
Coron Artery Dis; 2002 Aug; 13(5):275-81. PubMed ID: 12394652
[TBL] [Abstract][Full Text] [Related]
19. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
Philips M; Juul AG; Selmer J; Lind B; Thorsen S
Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Johansson L; Jansson JH; Boman K; Nilsson TK; Stegmayr B; Hallmans G
Stroke; 2000 Jan; 31(1):26-32. PubMed ID: 10625711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
